Ana P.
- Country
- Bulgaria
- Department
- Department “Daily stationary”, Floor 6, offices 11, 12 and 13
Research Overview
- A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GXV813 in Hospitalized Adults with Schizophrenia
- Efficacy and Safety Evaluation of ACP-204 Tartrate in Adults with Alzheimer's Disease Psychosis: A Double-Blind, Placebo-Controlled Study
- Evaluation of Long-Term Safety and Tolerability of ACP-204 Tartrate in Adults with Alzheimer's Disease Psychosis: A 52-Week Open-Label Extension Study
Data & Insights
Has run more than one trial at 87 of 183 partner sites.
Specializations
Cognitive and Schizophrenia Research
The investigator specializes in treating cognitive impairment associated with schizophrenia, conducting studies on novel therapeutic approaches. Their work extends to evaluating adjunctive treatments for patients with inadequate response to conventional antipsychotic therapy.
- Cognitive disorder management
- Schizophrenia treatment resistance
- Antipsychotic augmentation strategies
Mood Disorders
The investigator focuses on treating complex mood disorders, particularly bipolar I disorder and major depressive disorder with anhedonia. Their expertise includes evaluation of novel therapeutic agents for acute manic episodes and treatment-resistant depression.
- Bipolar mania management
- Treatment-resistant depression
- Anhedonia interventions
Neurodegenerative Disorders
The investigator specializes in treating neuropsychiatric manifestations of Alzheimer's disease, with particular emphasis on Alzheimer's disease psychosis. Their work includes both acute and long-term therapeutic interventions for these conditions.
- Alzheimer's disease psychosis treatment
- Long-term safety monitoring
- Neuropsychiatric symptom management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.